
This meta-analysis aimed to compare liver-related biochemical and coagulation biomarkers between individuals with Long COVID (LC) and controls. A search of PubMed/MEDLINE, Google Scholar, SciFinder, and Scopus was conducted from database inception to September 30, 2024. Sixty-one eligible studies, including 7172 participants, with 3404 individuals with LC and 3768 controls were identified. Among the liver-related biochemical markers, LC was associated with significantly higher alanine aminotransferase (ALT; SMD = 0.398; 95% CI: 0.118; 0.677), aspartate aminotransferase (AST; SMD = 0.352; 95% CI: 0.068; 0.637), and gamma-glutamyl transferase (GGT; SMD = 0.969; 95% CI: 0.194; 1.745) along with no significant changes in alkaline phosphatase and albumin. The composite liver biomarker index, based on those five markers was significantly higher among individuals with LC compared with controls, with a small effect size (SMD = 0.381; 95% CI: 0.149; 0.613). Among the complementary systemic and coagulation-related outcomes, lactate dehydrogenase activity (LDH; SMD = 0.489; 95% CI: 0.175; 0.802), prothrombin time (PT, SMD = 0.633; 95% CI: 0.077; 1.189), ferritin (SMD = 0.437; 95% CI: 0.069; 0.805), and D-dimer (SMD = 0.359; 95% CI: 0.144; 0.573) were significantly increased, whereas total protein was significantly decreased (SMD = -0.326; 95% CI: -0.631; -0.021). The present meta-analysis indicates that LC is associated with persistent abnormalities in several liver-related biochemical markers and coagulation-related outcomes. Further longitudinal studies are required to determine their clinical significance and long-term consequences.